{"entity":{"id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","aka":[],"tldr":"A phase 3 trial testing SHR-A1912 in diffuse large B-cell lymphoma, now recruiting.","summary":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT06929624, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Open-label, Randomised Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Planned enrolment is 280 participants (estimated). The study started in 2025-04-24 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06929624","url":"https://clinicaltrials.gov/study/NCT06929624"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-a1912"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06929624","phase":"3","setting":"A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","sponsor":"Suzhou Suncadia Biopharmaceuticals","started":"2025-04-24","startedType":"actual","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06929624/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"shr-a1912","kind":"drug","name":"SHR-A1912","route":"/drugs/shr-a1912/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}